Targeting TMPRSS2 ERG in Prostate Cancer
Abstract
TMPRSS2-ERG is an oncogenic translocation present in approximately half of all prostate cancers. Despite being an attractive therapeutic target, transcription factors have historically been difficult target pharmacologically. Furthermore, the exact of ERG in mediating tumorigenesis is unknown making it difficult to develop physiologically relevant assays to measure its activity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2016
- Accession Number
- AD1024135
Entities
People
- David Takeda
Organizations
- Dana–Farber Cancer Institute